Douglas S. Ingram has served as our President, Chief Executive Officer and a member of our Board since June 2017. Prior to his appointment, from December 2015 until November 2016, he served as the Chief Executive Officer and President and a Director of Chase Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company. Prior to joining Chase Pharmaceuticals, Mr. Ingram served as the President of Allergan, Inc., a pharmaceutical company, from July 2013 until it was acquired by Actavis in early 2015. At Allergan, he also served as President, Europe, Africa and Middle East from August 2010 to June 2013, and Executive Vice President, Chief Administrative Officer, and Secretary from October 2006 to July 2010, where he led Allergan’s Global Legal Affairs, Compliance, Internal Audit and Internal Controls, Human Resources, Regulatory Affairs and Safety, and Global Corporate Affairs and Public Relations departments.
Mr. Ingram also served as General Counsel of Allergan from January 2001 to June 2009 and as Secretary and Chief Ethics Officer from July 2001 to July 2010. With the acquisition of Allergan by Actavis, Mr. Ingram consulted as a special advisor to the Chief Executive Officer of Actavis. Mr. Ingram serves as a director of Pacific Mutual Holding Company, a parent company for subsidiaries engaged in a variety of insurance, financial services and other investment-related businesses, where he is a member of the Compensation Committee, the Governance and Nominating Committee, and the Member Interests Committee. Mr. Ingram received his J.D. from the University of Arizona and his Bachelor of Science degree from Arizona State University.
Guriqbal “Guriq” S. Basi, Ph.D. was appointed as our Chief Scientific Officer in September 2017. He has 30 years of experience serving in increasing roles of responsibility in the pharmaceutical and biotechnology industries.
Previously, Dr. Basi served as Elan’s Chief Science and Technology Officer and Head of Pre-clinical Development. He was also the former Chief Scientific Officer for Circuit Therapeutics, Inc. and Symic Biomedical. His thesis on gene regulation during muscle development, published in Molecular and Cellular Biology, was one of the earliest examples documenting alternative splicing in a cellular system. Over the course of his career, Dr. Basi has co-authored more than 25 peer-reviewed journal articles and is the owner of nearly a dozen U.S. patents. He served on the Scientific Advisory Board of the Parkinson’s Progression Marker Initiative, sponsored and funded by the Michael J. Fox Foundation, as well as an invited member of the Scientific Strategy and Planning Committee of the Alzheimer’s Drug Discovery Foundation.
Dr. Basi earned his Ph.D. from the University of Illinois at Chicago, and a B.S. in Biochemistry from the Ohio State University.
Diane Berry, Ph.D., has served as our Vice President of Global Health Policy and Government Affairs since December 2011.
Previously Dr. Berry worked for the federal government overseeing and implementing science and technology and public health activities, including CBRN defense efforts, across the legislative and executive branches. Dr. Berry served as a Subcommittee Staff Director and Senior Professional Staff Member for the House Committee on Homeland Security and worked at the Department of Homeland Security in the Office of Health Affairs in leadership roles including Chief Scientist, Director of Threat Characterization and Countermeasures, and Senior Biodefense Advisor. Previously Dr. Berry also served as a Senior Science Advisor at McKenna, Long, and Aldridge. She was a Science & Technology Policy Fellow through the American Association for the Advancement of Science.
Dr. Berry earned her Ph.D. in chemical engineering from Northwestern University and received her B.S. and M.S. in chemical/biochemical engineering from Tufts University.
Gary Charbonneau joined Sarepta in May 2018 as senior vice president, regulatory affairs, overseeing all aspects of our regulatory affairs organization including development strategy and global regulatory operations.
Mr. Charbonneau brings over 25 years of industry experience to Sarepta, having spent much of his career in regulatory affairs and quality assurance. Prior to joining Sarepta, he served as senior vice president of global regulatory affairs at Graybug Vision and senior vice president of global regulatory affairs at Chase Pharmaceuticals.
From September 2005 to June 2016, Mr. Charbonneau served as vice president of regulatory affairs at Allergan, where he held several leadership roles within the regulatory affairs organization during his 11-year career with the global pharmaceutical company. During his tenure at Allergan, Mr. Charbonneau was integral in building the global regulatory affairs function, in addition to working within various therapeutic areas including ophthalmology, urology, dermatology, and neurology. Mr. Charbonneau has also spent time at Amgen, Roche Bioscience, and Novo Nordisk in various roles during the course of his career in the life science and pharmaceutical industries. Mr. Charbonneau received his Bachelors of Science degree in Biological Science from California Polytechnic State University, San Luis Obispo and his Masters in Regulatory Science from the University of Southern California.
Bo Cumbo joined Sarepta in January 2013 and serves as our Chief Commercial Officer.
From June 2010 to January 2013, Mr. Cumbo worked at Vertex Pharmaceuticals, a biopharmaceutical company, where he served as Vice President of Sales and Treatment Education for the launch of Incivek, one of the most successful drug launches in the history of U.S. pharmaceuticals.
Prior to working at Vertex, Mr. Cumbo worked for Gilead Sciences, a biopharmaceutical company, for nine years in multiple commercial roles supporting the HIV, HBV and Cardiovascular franchises. Mr. Cumbo has experience in sales, marketing, national accounts, federal accounts, treatment education and commercial strategy, as well as in building effective teams for successful competitive launches.
Mr. Cumbo started his career at GSK and has over twenty years of pharmaceutical and biotechnology experience, with over ten specialty competitive launches during his career. Mr. Cumbo received his Bachelor of Science in Medical Technology from Auburn University.
Ian M. Estepan, joined Sarepta in January 2015 as head of investor relations. Mr. Estepan currently serves as chief of staff and vice president, corporate affairs, overseeing investor relations, corporate communications as well as program management. His focus is on incorporating patient perspectives into corporate strategic initiatives with the goal of expediting the advancement of clinical compounds through the regulatory process. By identifying endpoints related to patient reported outcomes, he works to identify new ways of assessing clinical effectiveness when traditional placebo controlled trials may not be feasible due to the limitations of studying patients with rare diseases.
Mr. Estepan brings 16 years of experience in healthcare investing to fund the development of promising drug candidates in a diverse number of therapeutic areas. Over the past 5 years, he has combined his financial and clinical acumen to speed clinical development and patient access to new therapies for patients with Duchenne muscular dystrophy.
Prior to joining Sarepta, from August 2001 to December 2014, Mr. Estepan was a senior portfolio manager for Wall Street’s Spectra Financial Group, where he was responsible for managing a multi-million dollar long-short portfolio of biotech, medtech and pharmaceutical stocks.
Mr. Estepan began his career as a financial analyst for Salomon Smith Barney in June 1999, participating in multi-billion dollar deals and creating financial models for the number-one ranked health care group in investment banking. From December 1999 to May 2001, Mr. Estepan served as director of strategic planning at The MusicBooth LLC, where he managed all aspects of patented, internet-based, technology start-up, serving the $20 billion audio advertising industry.
Mr. Estepan earned a Bachelor of Arts degree in psychology with a concentration in pre-medicine from Columbia University where he graduated Magna Cum Laude.
Ty Howton has served as our Senior Vice President, General Counsel and Corporate Secretary since November 2012.
From September 2011 to June 2012, Mr. Howton served as the Senior Vice President, Chief Legal Officer and as a member of the executive team at Vertex Pharmaceuticals Incorporated, a publicly-traded biotechnology company, and in this capacity he participated in the general management of the company and oversaw all aspects of the Vertex global legal and compliance departments. Mr. Howton served as Senior Vice President Legal from July 2012 to November 2012. Prior to his appointment as Chief Legal Officer at Vertex, Mr. Howton served as the Chief Compliance Officer from September 2009 to August 2011 and, in this capacity, he was responsible for designing and implementing the Vertex corporate compliance program as well as chairing the company's Corporate Compliance Committee. From 2003 to September 2009, Mr. Howton worked at Genentech, Inc., a biotechnology company, where he served in a number of legal roles before becoming the company's chief healthcare compliance officer in 2006. Prior to joining Genentech in 2003, Mr. Howton was a member of the Sidley Austin LLP corporate healthcare practice where he advised on corporate transactions involving life science companies and provided regulatory counsel.
Mr. Howton holds a B.A. from Yale University and a J.D. from Northwestern University School of Law.
Sandy Mahatme is our Executive Vice President, Chief Financial Officer and Chief Business Officer. He joined Sarepta in 2012 as Senior Vice President, Chief Financial Officer.
From January 2006 to November 2012, Mr. Mahatme worked at Celgene Corporation, a biopharmaceutical company, where he served in various roles, including Senior Vice President of Corporate Development, Senior Vice President of Finance, Corporate Treasurer and Head of Tax. While at Celgene, Mr. Mahatme built the treasury and tax functions before establishing the Corporate Development Department, focused on strategic, targeted initiatives including commercial development in emerging markets, acquisitions and licensing and global manufacturing expansion. Prior to working at Celgene, Mr. Mahatme worked for Pfizer Inc., a pharmaceutical company, for eight and a half years in senior roles in Business Development and Corporate Tax.
Mr. Mahatme started his career at Ernst & Young LLP where he advised multinational corporations on a broad range of transactions. Mr. Mahatme holds Master of Laws (LL.M.) degrees from Cornell Law School and NYU School of Law and is a member of the New York State Bar Association. Mr. Mahatme is also a board member of Flexion Therapeutics, Inc and Aeglea Biotherapeutics.
Joan Nickerson joined Sarepta in October 2016 and serves as our Vice President of Human Resources.
Ms. Nickerson’s experience includes over 20 years in human resources, working in higher education before transitioning into the biopharmaceutical industry. Ms. Nickerson started her career at Harvard University in the central human resources office and spent 13 years in multiple positions within the University in roles of increasing responsibility. Ms. Nickerson served as head of HR at Dyax, where she led human resources, facilities and administrative services until the company was acquired in 2016 by Shire plc. During her tenure at Dyax, Ms. Nickerson collaborated with the Executive Management team to drive employee engagement and a culture of accountability and collaboration to become the #2 Boston Globe’s Top Places to Work in 2015 (for medium-sized companies). She managed employee growth of 30% over a 3-year timeframe, maintaining a retention rate at >95%, and developed and launched a Leadership Development Program for key talent in the organization. Her expertise spans across the many facets of human resource management, including compensation and benefits, which have served both the company and its employees.
Ms. Nickerson holds a Bachelor’s degree in Business Administration from the University of Massachusetts, Lowell, and an MBA from Simmons College in Boston.
Gilmore O’Neill, M.B., M.M.Sc., was appointed as our Chief Medical Officer in June 2018, leading all clinical development, medical affairs, pharmacovigilance, and regulatory affairs.
In 2003, Dr. O’Neill joined Biogen as an associate director of clinical development, making the transition from practicing neurology full-time at Massachusetts General Hospital (MGH) to industry. During his 15-year career with Biogen, Dr. O’Neill held leadership roles of increasing responsibility in clinical research and development. From November 2016 to June 2018, Dr. O’Neill served as Biogen’s senior vice president, late-stage clinical development and oversaw development programs for Alzheimer’s disease, movement disorders, acute neurology, multiple sclerosis, pain, neuromuscular disease, gene and cell therapy, and rare diseases. He played a leadership role in seeking, receiving and maintaining global marketing approvals for Tecfidera®, Zinbryta®, Plegridy® and Spinraza®.
Dr. O’Neill is a member of the American Academy of Neurology and a board-certified neurologist (ABPN), licensed to practice medicine in the state of Massachusetts. He served as director of the leukodystrophy service and chief resident in neurology during his time at MGH as full-time physician, and has maintained his clinical appointment at MGH with a sub-specialty interest in neuromuscular diseases and inherited leukodystrophies. From 1997 to 2015, he served as a clinical instructor in neurology at Harvard Medical School. Dr. O’Neill also serves on the board of directors of the Massachusetts Biotechnology Council (MassBio).
Dr. O’Neill received a Bachelor of Medicine degree at University College Dublin and a Master of Medical Sciences degree from Harvard University. He is the recipient of numerous awards in science and medicine, in-cluding the Lefler Fellowship in the Department of Neurobiology at Harvard Medical School. Dr. O’Neill is the author of numerous publications on multiple sclerosis, has served as a neurology peer reviewer for medical literature, and lectures in the United States and globally on advances in neurology and neurological research.
Louise Rodino-Klapac, Ph.D. has served as our Vice President, Gene Therapy since June 2018.
Renowned for her work in molecular genetics and gene therapy, Dr. Rodino-Klapac was head of the laboratory for gene therapy research for muscular dystrophies at Nationwide Children’s Hospital prior to joining Sarepta.
From July 2010 to June 2018, Dr. Rodino-Klapac was an Associate Professor, Department of Pediatrics, The Ohio State University College of Medicine and Principal Investigator, Center for Gene Therapy for The Research Institute at Nationwide Children's Hospital and a faculty member of the Biomedical Sciences Graduate Program and Molecular, Cellular, and Developmental Biology Graduate Programs, The Ohio State University College of Medicine. Dr. Rodino-Klapac also served as the Ruth L. Kirschstein F32 Post-doctoral Fellow, National Institutes of Health, The Research Institute at Nationwide Children's Hospital; and was a post-doctoral researcher, Center for Gene Therapy, The Research Institute at Nationwide Children's Hospital.
In February 2017, Dr. Rodino-Klapac co-founded Myonexus Therapeutics, Inc., a clinical stage gene therapy biotech company focused on treatment of Limb girdle muscular dystrophy (LGMD). Dr. Rodino-Klapac serves as acting chief scientific officer of Myonexus and in early May 2018, Sarepta announced a collaboration with Myonexus to develop potentially transformative gene therapies to treat five distinct forms of LGMD.
Dr. Rodino-Klapac is the recipient of numerous awards, including the Forty Under 40 Award by Columbus Business First, and the Department of Pediatrics Outstanding Junior Faculty Award for Innovation. She’s the author of numerous publications, among them papers published in The New England Journal of Medicine, Annals of Neurology, and Pediatric Neurology.
Dr. Rodino-Klapac received her bachelor’s degree in biology from Kings College, and a Ph.D. in molecular genetics from The Ohio State University.